Freeline Therapeutics (FRLN)
NASDAQ: FRLN
· Real-Time Price · USD
6.49
0.01 (0.15%)
At close: Feb 16, 2024, 9:37 PM
Freeline Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 5K | 617K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 383.76K | 434.39K | 322.9K | 317.36K | 402.54K | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -378.76K | 182.61K | -322.9K | -317.36K | -402.54K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -12.27M | -15.65M | -20.08M | -19.88M | -23.51M | -26.89M | -28.17M | -34.33M | -35.3M | -38.81M | -33.94M |
Interest Income | 98K | 34K | 206K | 273K | 296K | 251K | 84K | n/a | 85K | 125K | 140K |
Pretax Income | -12.05M | -16M | 1.33M | -22.73M | -14.84M | -24.32M | -26.71M | -34.39M | -30.86M | -39.86M | -34.94M |
Net Income | -12.09M | -16.01M | 1.17M | -23M | -14.89M | -24.35M | -26.73M | -34.7M | -30.88M | -39.87M | -34.95M |
Selling & General & Admin | 6.4M | 9.5M | 8.05M | 5.64M | 8.73M | 8.05M | 8.22M | 7.35M | 12.6M | 14.54M | 10.08M |
Research & Development | 5.79M | 8.83M | 10.89M | 12.64M | 14.78M | 18.84M | 19.95M | 24.6M | 22.7M | 24.27M | 23.86M |
Other Expenses | -34K | -591K | -261K | -267K | -583K | -335K | -386K | -658K | 3.86M | -1.63M | -1.73M |
Operating Expenses | 12.03M | 18.12M | 18.68M | 18.02M | 22.93M | 26.56M | 27.79M | 31.4M | 34.81M | 38.35M | 33.34M |
Interest Expense | n/a | n/a | n/a | 6.39M | 296K | 251K | n/a | n/a | 85K | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 12.03M | 18.12M | 18.68M | 18.02M | 22.93M | 26.56M | 27.79M | 31.4M | 34.81M | 38.35M | 33.34M |
Income Tax Expense | 41K | 6K | 162K | 272K | 50K | 24K | 22K | 313K | 13K | 7K | 9K |
Shares Outstanding (Basic) | 4.36M | 4.34M | 4.34M | 4.33M | 4.33M | 4.3M | 2.84M | 2.38M | 2.38M | 2.38M | 2.38M |
Shares Outstanding (Diluted) | 4.36M | 4.34M | 4.34M | 4.33M | 4.33M | 4.3M | 2.84M | 2.38M | 2.38M | 2.38M | 2.38M |
EPS (Basic) | -2.77 | -3.69 | 0.30 | -5.31 | -3.44 | -5.66 | -9.4 | -14.56 | -12.96 | -16.76 | -14.7 |
EPS (Diluted) | -2.77 | -3.69 | 0.30 | -5.31 | -3.44 | -5.66 | -9.4 | -14.56 | -12.96 | -16.76 | -14.7 |
EBITDA | -11.56M | -19.13M | -37.51M | -16.03M | -22.52M | -26.08M | -27.24M | -30.79M | -34.22M | -37.74M | -32.77M |
EBIT | n/a | n/a | -37.83M | -14.89M | -14.55M | -23.84M | -27.79M | -34.47M | -31.35M | n/a | n/a |
Depreciation & Amortization | 386K | 433K | -17.42M | 3.85M | 988K | 814K | 927K | 611K | 588K | 618K | 573K |